Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Interesting

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Jul 24, 2021 7:33pm

100 Views

Post# 33601415

RE:RE:RE:RE:Interesting

I dont think each site gets to "experiment" with the protocol. Is this webpage new? Maybe this is an updated protocol that hasn't made it too the clinicaltrial website or other clinical site websites.

Maybe it's just to control a low grade side effect.

scarlet1967 wrote:

SPCEO1 wrote: What conclusions can we draw from this new addition? Have THTX seen something in the first patients that has led to the addition of this drug? Could it improve outcomes?

scarlet1967 wrote: "Melphalan flufenamide is indicated in combination with dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma, with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody."

Another PDC also uses the same combination.

Using steroids for cancer patients is common for many reasons some listed below. Melphalan flufenamide was approved not long ago also a PDC, they also use the steroid for better management of side effects mostly also to kill cancer cells.

It looks like only one Center is experimenting with the combination of TH1902 and the steroid. If no drug drug interactions it will make the treatment more tolerable/effective.

“Steroids have many indications for use in palliative care. Dexamethasone is the most commonly used corticosteroid due to the smaller number of tablets at higher doses, and the option for subcutaneous route if necessary. Steroids are substances that are naturally produced in the body.

“Steroids can also be made in a laboratory as drugs. They can be used in cancer treatment:

to help destroy cancer cells and make chemotherapy more effective

to reduce an allergic reaction to certain drugs

as anti-sickness drugs

to improve appetite

to reduce symptoms such as pain caused by swelling (inflammation) around a cancer.

The most commonly used steroids are:

hydrocortisone

dexamethasone

methylprednisolone

prednisolone.”